Search

A recent wave of pharmacologic and technologic innovations has revolutionized our management of retinal diseases. Many of these advancements have demonstrated efficacy and can increase the quality of life while potentially reducing complications and decreasing the burden of care for patients. Some advances, such as longer-acting anti-vascular endothelial growth factor agents, port delivery systems, gene therapy, and retinal prosthetics have been approved by the US Food and Drug Administration, and are available for clinical use. Countless other therapeutics are in various stages of development, promising a bright future for further improvements in the management of the retinal disease. Herein, we have highlighted several important novel therapies and therapeutic approaches and examine the opportunities and limitations offered by these innovations at the new frontier. KEY MESSAGESNumerous pharmacologic and technologic advancements have been emerging, providing a higher treatment efficacy while decreasing the burden and associated side effects.Anti-vascular endothelial growth factor (anti-VEGF) and its longer-acting agents have dramatically improved visual outcomes and have become a mainstay treatment in various retinal diseases.Gene therapy and retinal prosthesis implantation in the treatment of congenital retinal dystrophy can accomplish the partial restoration of vision and improved daily function in patients with blindness, an unprecedented success in the field of retina.

Purpose: At present, Argus II is the only retinal prosthesis approved by the US Food and Drug Administration that induces visual percepts in people who are blind from end-stage outer retinal degenerations such as retinitis pigmentosa. It has been shown to work well in sparse, high-contrast settings, but in daily practice visual performance with the device is likely to be hampered by the cognitive load presented by a cluttered real-world environment. In this study, we investigated the effect of a stereo-disparity-based distance-filtering system on four experienced Argus II users for a range of tasks: object localization, depth discrimination, orientation and size discrimination, and people detection and direction of motion., Methods: Functional vision was assessed in a semicontrolled setup using unfiltered (normal camera) and distance-filtered (stereo camera) imagery. All tasks were forced choice designs and an extension of signal detection theory to latent (unobservable) variables was used to analyze the data, allowing estimation of person ability (person measures) and task difficulty (item measures) on the same axis., Results: All subjects performed better with the distance filter compared with the unfiltered image ( P   < 0.001 on all tasks except localization)., Conclusions: Our results show that depth filtering using a disparity-based algorithm has significant benefits for people with Argus II implants., Translational Relevance: The improvement in functional vision with the distance filter found in this study may have an important impact on vision rehabilitation and quality of life for people with visual prostheses and ultra low vision., Competing Interests: Disclosure: A. Kartha, None; R. Sadeghi, None; M.P. Barry (E); C. Bradley, None; P. Gibson (E); A. Caspi (C, P); A. Roy (E); G. Dagnelie (C, P), (Copyright 2020 The Authors.)